Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Berzelii Pharma AB
AB
Active
Org 5594833427
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2024
1-4 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Berzelii Pharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2024
Income statement
SEK thousands
Item
2024
Revenue
—
Staff expenses
—
EBITDA
−67
Depreciation & amort.
—
EBIT
−67
Net financials
—
Profit before tax
−67
Tax
—
Net profit
−67
Balance sheet
SEK thousands
Item
2024
Total assets
104
Equity
58
Long-term debt
—
Short-term debt
47
Total debt
47
Financial ratios
5-year trend
EBITDA-margin
-6748500.0%
This company
15.8%
Market median
-42712125% vs market
2024
2024
Soliditetsgrad
55.1%
This company
38.2%
Market median
+44% vs market
2024
2024
Egenkapitalforrentning
-117.3%
This company
18.4%
Market median
-738% vs market
2024
2024
Nettoresultatgrad
-6748500.0%
This company
8.1%
Market median
-83314915% vs market
2024
2024
Aktivomsætning
0.00×
This company
1.12×
Market median
-100% vs market
2024
2024
Gæld/egenkapital
0.82×
This company
0.62×
Market median
+32% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-05-14 – 2024-12-31
View
PDF
More on Berzelii Pharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
